McClellan’s FDA Legacy? Decisive Role In Product Development Priorities

Related Content

CDRH “Innovation Initiative” Highlights Efforts To Speed Premarket Process

CBER’s Goodman Eyes Tissue, Blood Test Innovation Through Post-9/11 Lens

On FDA Critical Path, Device Industry Demands Independence From Pharma

FDA Critical Path Office Would Define Up To Four “Opportunities” Per Year

CDRH Keeps An Eye On Needle-Free Injector Policy Development

CDRH Promotes Bayesian Tool To Speed Approvals; Statistical Rigor Required

FDA Science Board Previews Device “Critical Path” R&D Opportunity List

Device Review Templates Are Milestones On Road To “Critical Path” – CBER

Imaging Subgroup Formed Under NCI/FDA Oncology Task Force

Interdisciplinary Teams Focused On Imaging Research Needed – NIH Director